Diabetes Care: A new choice for patients with type 1 diabetes-a tubeless, automatic insulin delivery system in the body to try!

In recent years, rapid innovations in blood glucose sensor and insulin pump technology have changed diabetes care
.

However, blood sugar control is still not ideal for all people, especially type 1 diabetes (T1DM), which has a huge burden of disease

Diabetes, especially type 1 diabetes (T1DM), has a huge disease burden, especially type 1 diabetes (T1DM), has a huge disease burden, type 1 diabetes, hypoglycemia

Currently, there are four systems available for commercial use in the United States and Europe
.

Each system differs through the combination of specific equipment, system configuration and settings, and proprietary dosing algorithms

Schematic diagram

So far, all systems have adopted a tethered pump, which delivers insulin through a tube (46-110cm) connecting the pump and the infusion site.
Therefore, the pump must be located somewhere on the person to accommodate the tube (such as Belts, pockets)
.

The algorithm is either hosted on the pump itself, in which case the tethered device must be frequently accessed for user interaction, or hosted on the smartphone that controls the pump, in which case the smartphone must remain within the communication range of the pump Inside

The pump must be located somewhere on the person's body to accommodate the tube (e.

The FDA management system is the first tubeless, automatic insulin delivery system in the body with customizable blood glucose targets

This single-arm, multicenter, prospective study recruited 112 children (6-13.
9 years old) and 129 adults (14-70 years old) T1DM participants
.

After a 2-week standard treatment phase (conventional insulin regimen), a 3-month automatic insulin delivery is performed

child

Results A total of 235 participants (98% of the total number, including 111 children and 124 adults) completed the study
.

In general, children’s HbA1c was significantly reduced by 0.

In general, children’s HbA1c was significantly reduced by 0.

Individual HbA1c results of all participants before (baseline) and after (follow-up) 3 months of automated insulin delivery

Compared with standard therapy, the range of time for children increased by 15.
6±11.
5% or 3.
7 hours/day, and the time for adults increased by 9.
3±11.
8% or 2.
2 hours/day
.

At the same time, the duration of hypoglycemia <70 mg/dL was reduced in adults (2.

Compared with standard therapy, the range of time for children increased by 15.

In summary, this tubeless automatic insulin delivery system is safe, enabling participants to significantly increase HbA1c levels and the time within the target blood glucose range, and the incidence of hypoglycemia is very low
.
In summary, this tubeless automatic insulin delivery system is safe, enabling participants to significantly increase HbA1c levels and the time within the target blood glucose range, and the incidence of hypoglycemia is very low
.

 

references:

Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes.
Diabetes Care 2021 Jul; 44(7): 1630-1640.
https://doi.
org/10.
2337 /dc21-0172

Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes.
Leave a message here